Unfortunately, to date, no single cathepsin inhibitor has been clinically approved for the treatment of cathepsin-related diseases, such as cancer or inflammatory disorders [190], which limits the initial enthusiasm for developing cathepsin-targeted COVID-19 medicines. This evidence concerns the gene CTSS and cancer.